Formulation Development
Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248
Kinnate Biopharma Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for KIN-3248, a next-generation….
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
Revive Therapeutics Ltd. recently provided an update on the company’s US FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with….
VYNE Therapeutics Announces Phase 1b Data for FMX114 From Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
VYNE Therapeutics Inc. recently announced it has completed the Phase 1b portion of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate…
Recce Pharmaceuticals Announces Positive Safety Data From Second Cohort of Phase 1 Clinical Trial Evaluating Healthy Subjects Intravenously Dosed With RECCE 327
Recce Pharmaceuticals Ltd recently reported further positive data from its Phase 1 intravenous (IV) clinical trial of RECCE 327 (R327), demonstrating safety and tolerability among…
ChemoCentryx Announces EU Approval of TAVNEOS for the Treatment of ANCA-Associated Vasculitis
ChemoCentryx, Inc. recently announced TAVNEOS (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of…
Avomeen to Become Element
In early 2021 , Avomeen was acquired by Element Materials Technology, advancing Element’s commitment to providing best-in-class scientific solutions to the vital Life Sciences sector,…
Treadwell Therapeutics Engages Genezen to Advance its T cell Receptor-Based Cell Therapy Pipeline
Treadwell Therapeutics and Genezen have recently confirmed a partnership agreement to accelerate the production of T cell receptor (TCR)-based candidates to address unmet needs in cancer patients…..
Petros Pharmaceuticals Launches Two Self-Selection Studies for ED Drug
Petros Pharmaceuticals, Inc. recently initiated two self-selection studies for its erectile dysfunction (ED) drug STENDRA (avanafil). The results of these studies will be part of…
Catalent Launches New Xpress PharmaceuticsT Service to Expedite Development of Oral Drugs for Adaptive Phase 1 Clinical Trials
Catalent recently announced the launch of its new Xpress Pharmaceutics service, designed to accelerate the development of oral drugs through Phase 1 clinical studies. By integrating formulation….
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 & Pembrolizumab for Treatment of Head & Neck Cancer & Reports FDA’s Fast Track Designation
HOOKIPA Pharma Inc. recently announced the first patient has been dosed with HB-200 in combination with pembrolizumab for the treatment of first-line advanced/metastatic Human Papillomavirus 16….
Resverlogix Announces Commencement of Patient Enrollment & Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
Resverlogix Corp. recently announced enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton. The trial will evaluate the safety and efficacy of apabetalone….
Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program
Artizan Biosciences, Inc. recently announced the selection of its lead product candidate, ARZC-001, for the treatment of inflammatory bowel disease (IBD). Discovered internally and….
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA for Treatment of Melanoma
Evaxion Biotech A/S recently announced it has received clearance from the Australia Therapeutic Goods Administration to initiate a Phase 2b trial of its patient specific cancer immunotherapy EVX-01 in combination with….
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect & Pharmacokinetics Data for BETR-001
BetterLife Pharma Inc. recently announced it has obtained positive results from an in vivo oral bioavailability and food-effect pharmacokinetic (PK) study on BETR-001 in beagle…
Lonza, Forbion, and BioGeneration Ventures Extend Collaboration to Add Development & Manufacturing Services of Small Molecules
Forbion, a leading venture capital firm building life sciences companies, BioGeneration Ventures (BGV), its joint venture partner and specialized life sciences venture capital firm focusing…
EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III & Stage IV Non-Small Cell Lung Cancer
EQRx, Inc. recently announced data from its partner CStone Pharmaceuticals’ two pivotal Phase 3 studies of the anti-PD-L1 monoclonal antibody sugemalimab for the treatment of…
FORMULATION FORUM - Formulation & Process of Lipid Nanoparticles for Delivery of Small Molecules & Biologicals
Jim Huang, PhD, explains how recently, lipid nanoparticles have emerged as a drug delivery system for biologicals, especially for the COVID-19 mRNA vaccines in which LNPs play a vital role in transporting mRNA into the target cells.
ORGAN-ON-A-CHIP - A Novel Way to Accurately Test Delivery of Non-Standard Formulations
David Hughes, PhD, says ultimately, the goal of OOC technology is to improve the translatability of data between the lab and the clinic. Through a lung-on-a-chip approach, it is possible to recreate the histoarchitecture, phenotype, and function of bronchial and alveolar areas of the lung.
EXOSOMES - The Next Evolution in Therapy Delivery Beyond the Cell Membrane: The Promise of Exosomes
Linda Marbán, PhD, says perhaps the best way to get past the cell membrane is to deliver contents the same way that cells send information to each other. And that is by the exosome, which in the case of targeted therapy delivery, has been identified as an alternative that shows powerful promise.
Clinical Trial Begins in the UK to Investigate 3-in-1 High Blood Pressure Pill
George Medicines recently announced its proprietary triple low-dose combination pill, GMRx2, will be trialed in UK patients with high blood pressure (hypertension), in a collaboration…
